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Pulsatile shear (PS) and oscillatory shear (OS) elicit distinct
mechanotransduction signals that maintain endothelial homeo-
stasis or induce endothelial dysfunction, respectively. A subset of
microRNAs (miRs) in vascular endothelial cells (ECs) are differentially
regulated by PS and OS, but the regulation of the miR processing
and its implications in EC biology by shear stress are poorly
understood. From a systematic in silico analysis for RNA binding
proteins that regulate miR processing, we found that nucleolin
(NCL) is a major regulator of miR processing in response to OS and
essential for the maturation of miR-93 and miR-484 that target
mRNAs encoding Krüppel-like factor 2 (KLF2) and endothelial nitric
oxide synthase (eNOS). Additionally, anti–miR-93 and anti–miR-484
restore KLF2 and eNOS expression and NO bioavailability in ECs
under OS. Analysis of posttranslational modifications of NCL identi-
fied that serine 328 (S328) phosphorylation by AMP-activated
protein kinase (AMPK) was a major PS-activated event. AMPK phos-
phorylation of NCL sequesters it in the nucleus, thereby inhibiting
miR-93 and miR-484 processing and their subsequent targeting of
KLF2 and eNOS mRNA. Elevated levels of miR-93 and miR-484 were
found in sera collected from individuals afflicted with coronary ar-
tery disease in two cohorts. These findings provide translational
relevance of the AMPK–NCL–miR-93/miR-484 axis in miRNA process-
ing in EC health and coronary artery disease.
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Vascular endothelium responds differentially to pulsatile andoscillatory shear stresses (PS and OS stresses, respectively)
which are athero-protective and athero-prone, respectively. Shear
stress acting on vascular endothelial cells (ECs) regulates a
plethora of microRNAs (miRs), which in turn positively or nega-
tively affect endothelial function. miR maturation is a multistep
process involving highly orchestrated events in both the nucleus
and cytoplasm. Following transcription in the nucleus, primary
miRs (pri-miRs) containing a stem loop structure undergo two
sequential cleavage steps initiated by removal of the 3′ and 5′
terminal ends by Drosha, a component of the microprocessor
complex. Subsequently, the premiRs are shuttled from the nucleus
to the cytoplasm and become truncated, resulting in single-
stranded miRs that are 21–23 nucleotides in length. These ma-
ture miRs bind to the miR-induced silencing complex (miRISC)
containing an argonaute (AGO) protein that targets mRNAs for
degradation via miR seed sequence complementarity. In the con-
text of vascular biology, shear stress-regulated miRs modulate EC
proliferation, inflammation, nitric oxide (NO) bioavailability, and
intercellular communication (1–6). Although the effects of PS and
OS on miRs have been well studied, the mechanistic basis for miR
processing in ECs responding to distinct shear stress is unknown.
Nucleolin (NCL) is a multidomain protein that shuttles be-
tween the nucleus and cytoplasm to coordinate various functions
(7). Through four tandem nucleotide-binding domains, NCL
binds to RNA stem loop structures containing a UCCCGA
consensus sequence (8, 9). With respect to miR processing, NCL
can interact with the microprocessor complex in the nucleus to
promote the processing of miRs that contain GU-enriched se-
quences (10). To date, studies of NCL in ECs have focused on
proliferation, adhesion, and migration of ECs in angiogenesis
associated with tumor biology (11–13). Among the PS-activated
kinases, AMP-activated protein kinase (AMPK) regulates cel-
lular homeostasis via phosphorylating targets predominantly
containing a βθβXXX(S/T)XXXθ consensus sequence (β = basic
amino acid, θ = hydrophobic amino acid, and X = any amino
acid) (14, 15). Of relevance here is that the amino acid sequences
flanking Ser-328 of NCL (NCL S328) correspond to the con-
sensus sequence for AMPK phosphorylation.
In this study, we identified that NCL S328 is phosphorylated
by AMPK and that the phosphorylation state of NCL determines
the binding of miR-93 and miR-484 to NCL. In response to PS,
AMPK phosphorylates NCL S328, resulting in NCL nuclear lo-
calization and subsequent inhibition of the binding of NCL/miR-93
and NCL/miR-484 complexes to the microprocessor complex.
Significance
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lium. Nonphosphorylated nucleolin facilitates the maturation
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patients with coronary artery disease.
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The inhibition of NCL-dependent miR-93/miR-484 processing
promotes EC homeostasis through the elevated expression of
Krüppel-like factor 2 (KLF2) and endothelial nitric oxide synthase
(eNOS). This AMPK–NCL–miR-93/miR-484 axis introduces an
athero-protective mechanotransduction mechanism in ECs.
Results
AMPK Phosphorylation of NCL in ECs in Response to PS. To screen for
miR-binding proteins that are likely to participate in miR pro-
cessing regulated by PS, a four-step in silico screening strategy
was used (a flowchart is shown in SI Appendix, Fig. S1). Initially,
we screened miRbase for miR sequences that are conserved
among different mammalian species. Next, the miR sequences
that were conserved in human, mouse, and rat were used to
screen for miR-binding proteins that contain the consensus
RNA-binding sequences defined in the A daTabase of RNA
binding proteins and AssoCiated moTifs (ATtRACT) database
(https://attract.cnic.es/). Because AMPK regulates atheropro-
tective flow-sensitive miRs (16, 17), these putative miR-binding
proteins were cross-referenced to the AMPK phosphorylation
target proteome (14, 15) to identify miR-binding proteins that
are also AMPK targets (SI Appendix, Fig. S1) (Dataset S1). Fi-
nally, the identified miR-binding proteins were annotated with
transcriptomic information—for example, RNA-sequencing
(RNA-seq) datasets—from PS and OS experiments previously
reported (18). A total of 66 miR-binding proteins were thus
identified by this four-step screening process (Dataset S2).
Among these, NCL was predicted to regulate the largest number
of miRs (Fig. 1A).
Furthermore, the putative AMPK phosphorylation sites of
NCL, namely S328 and S571, were found to be highly conserved
among human, mouse, and rat. The location of these two Ser
residues at the four-tandem nucleotide binding motifs suggested
that their phosphorylation status might alter RNA binding (Fig.
1B). Next, we investigated if AMPK could phosphorylate NCL,
and if so, whether AMPK phosphorylation of NCL regulated miR
processing. In vitro kinase assays demonstrated that phosphate
incorporation into NCL occurred only in the presence of AMPK
(Fig. 1C). Furthermore, treatment of the wild-type (AMPK+/+),
but not AMPKα1 & AMPKα2−/− (AMPK−/−), mouse embryonic
fibroblasts (MEFs) with 5-aminoimidazole-4-carboxamide ribo-
nucleotide (AICAR), an AMPK pharmacological activator, shifted
the isoelectric point of NCL toward a lower pH (Fig. 1D). These
results are consistent with AMPK phosphorylation of NCL, be-
cause phosphorylated NCL would shift the isoelectric point toward
a lower pH. Of the 11-mer NCL peptides containing S328, S571,
and the de-phospho Ser-to-Ala mimetics (i.e., S328A and S571A),
only the NCL S328 peptide was phosphorylated to a similar extent
as the control SAMS peptide (Fig. 1E). Additionally, the NCL
S328A peptide competitively inhibited SAMS peptide phosphory-
lation (Fig. 1F), indicating the specificity of AMPK phosphorylation
of NCL S328. We transfected human umbilical vein endothelial
cells (HUVECs) with Flag-tagged NCL (Flag-NCL) wild type or
Flag-NCL S328A mutant, and then stimulated the transfected
cells with AICAR. Immunoprecipitation (IP) with anti-Flag an-
tibody and immunoblotting with anti–phospho-Ser antibody
showed significantly greater NCL S328 phosphorylation com-
pared with cells transfected with NCL S328A constructs (Fig.
1G). With a newly created antiphospho-NCL S328, we found
that NCL S328 phosphorylation in HUVECs was higher under
PS than with OS (Fig. 1H). The higher level of phosphorylation
of NCL S328 was also evident in the mouse thoracic aorta (TA),
which is exposed to atheroprotective flow, in comparison with
the aortic arch (AA), which experiences atheroprone flow (Fig.
1I). In summary, the results illustrated in Fig. 1 demonstrate that
PS increases NCL S328 phosphorylation via AMPK in HUVECs.
NCL Involvement in Flow-Regulated miR. To investigate the func-
tional consequences of NCL S328 phosphorylation, cellular
fractionation of HUVECs revealed nuclear localization of NCL
upon AMPK activation with AICAR, which had little effect
when AMPK was knocked down (Fig. 2A). These results were
validated in HUVECs treated with AICAR or metformin (an
AMPK agonist) and immunostained with anti-NCL (SI Appendix,
Fig. S2A). However, little changes in NCL expression were de-
tected in HUVECs stimulated with AICAR or PS (SI Appendix,
Fig. S2 B and C). With respect to miR processing in ECs under
different flow patterns, NCL interaction with the miR micropro-
cessor Drosha was higher under OS than with PS (Fig. 2B). The
OS-increased interaction between NCL and Drosha was mimicked
by HUVECs transfected with NCL S328A (dephosphomimetic
mutant) compared with NCL S328D (phosphomimetic mutant)
(Fig. 2C). These results suggested that NCL regulates miR pro-
cessing in ECs in part due to increased NCL binding to Drosha
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Fig. 1. AMPK phosphorylation of NCL. (A) miR binding protein ranking based on the number of putative targeted miRs. (B) Functional domains and AMPK
phosphorylation consensus sequences on human, mouse, and rat NCL. (C) In vitro kinase assay demonstrating the phosphorylation of recombinant NCL by
AMPK. (D) Isoelectric focusing of NCL isolated from AMPK+/+ and AMPK−/− MEF cells. (E) In vitro kinase assay using recombinant AMPK and NCL peptides
(11-mers) illustrated in B. (F) Peptide competition assay against SAMS peptide and increasing concentrations of S328A 11-mer peptide. (G) Immunoblot with
p-Serine antibody for FLAG-NCL immunoprecipitated from HUVEC treated with AICAR for 10 min. (H and I) Immunoblotting of lysates from HUVECs under PS
and OS as well as TA and AA. *P < 0.05. Data are mean ± SEM from three independent experiments.
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(19). Furthermore, the premiRs containing UCCCGA required
for NCL/RNA binding (20) were ranked based on the conservation
of this binding sequence among mammalian species (shown in
Dataset S1). Through this screening process, miR-93 (in which
both -3p and -5p strands are expressed) and miR-484 were iden-
tified to contain the UCCCGA sequence for NCL binding, while
exhibiting the highest degree of species conservation including
human, mouse, and rat (Fig. 2D and E and SI Appendix, Table S1).
NCL Regulates Processing of miR-93 and miR-484.Given that PS and
OS differentially regulate AMPK activity (21) and that AMPK
can phosphorylate NCL (Fig. 1), we investigated the role of
AMPK in NCL-regulated miR-93 and miR-484 processing. As
illustrated in Fig. 3A, the levels of miR-93 and miR-484 were
lower in HUVECs exposed to PS compared with OS. This dif-
ference in expression level was not observed in cells transfected
with AMPK siRNA (siAMPK) (Fig. 3A). Similar results were
obtained with AMPK−/−, compared with AMPK+/+ MEFs (SI
Appendix, Fig. S3A). Given that AMPK phosphorylates NCL
S328 under PS, HUVECs were transfected with plasmids over-
expressing wild-type NCL S328, NCL S328A, or NCL S328D. As
illustrated in Fig. 3B, the expression levels of miR-93 and miR-
484 were higher in HUVECs overexpressing NCL S328A com-
pared with NCL S328 or NCL S328D. Furthermore, NCL
binding to premiR-93 and premiR-484 was also increased in cells
overexpressing NCL S328A and decreased in HUVECs over-
expressing NCL S328D (SI Appendix, Fig. S3B). Because OS in-
creased the binding of NCL to Drosha (Fig. 2C), we investigated
whether OS regulates the processing of miR-93 and miR-484,
thereby increasing their expression levels. As illustrated in Fig.
3C, the binding of premiR-93 and premiR-484 to NCL was at-
tenuated in cells under PS compared with OS. However, such
differential binding of premiR-93/484 to NCL was not observed if
AMPK was knocked down (Fig. 3C). Similar results were observed
in experiments with AMPK+/+ and AMPK−/− MEFs (SI Appendix,
Fig. S3C) and HUVECs infected with adenovirus overexpressing
the constitutively activated AMPK (Ad-AMPK, simulating PS ac-
tivation of AMPK) (SI Appendix, Fig. S3D). To confirm the in-
volvement of NCL in OS-mediated premiR-93 or premiR-484
processing, HUVECs were transfected with control or NCL
siRNA together with plasmids overexpressing premiR-93 or
premiR-484 (simulating OS induction) followed by analyzing the
binding of miR to miRISC complex (i.e., AGO2). As illustrated in
SI Appendix, Fig. S3E, miR-93 and miR-484 overexpression resulted
in the increased binding of miR-93 and miR-484 to AGO2, which
was not seen in HUVECs transfected with NCL siRNA. Moreover,
the levels of AGO2-associated miR-93 and miR-484 were higher in
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HUVECs overexpressing NCL S328A compared with S328 or
S328D (Fig. 3D). Consistent with these observations, aortic ECs
isolated from EC-specific AMPKα2−/−mice (EC-AMPKα2−/−) had
increased levels of miR-93-3p, miR-93-5p, and miR-484 compared
with those from EC-AMPKα2+/+ littermates (Fig. 3E). Further-
more, the levels of miR-93 and miR-484 and their associations with
NCL were higher in the mouse AA than those in TA (Fig. 3F and
SI Appendix, Fig. S3F). Taken together, the results summarized in
Fig. 3 and SI Appendix, Fig. S3 suggest that PS down-regulates,
while OS up-regulates, miR-93 and miR-484 processing, which
are dependent on AMPK phosphorylation of NCL S328.
NCL Regulation of miR-93 and miR-484 Evokes Endothelial Dysfunction.
Because OS promotes endothelial dysfunction (22) and the results
illustrated in Fig. 3 showed that OS increases the expression of
miR-93 and miR-484, we hypothesized that miR-93 and miR-484
target mRNAs important for EC homeostasis. To identify miR-93
and miR-484 targets, we initially identified mRNAs that are down-
regulated in ECs by OS [obtained from our previously generated
RNA-seq datasets (18)] and by miR-93 or miR-484 overexpression
[obtained from online data mining (23)]. Among the putative
mRNA targets (Datasets S3 and S4), markers of functional en-
dothelium including KLF2 and eNOS were down-regulated by OS
and miR-93 (6, 24) (Fig. 4A). Additionally, eNOS was down-
regulated by OS and miR-484 (Fig. 4B). We also identified that
KLF2 and eNOS mRNAs contain a miR-93 seed sequence while
eNOS mRNA also contains a miR-484 seed sequence in their
3′UTR (SI Appendix, Fig. S4A), suggesting that they would be
direct targets of miR-93 or miR-484. To validate these in silico
predictions, HUVECs were transfected with premiR-93 or premiR-
484. As illustrated in Fig. 4C, the expression of endogenous KLF2
and eNOS mRNAs was down-regulated by miR-93, whereas
eNOS was down-regulated by miR-484. To confirm these results,
HUVECs were transfected with miR-93 or miR-484 over-
expression plasmid and then subjected to PS. As illustrated in SI
Appendix, Fig. S4 B and C, KLF2 and eNOS mRNA levels were
attenuated in miR-overexpressing cells compared with control.
Additionally, NCL S328A overexpression (simulating OS) re-
duced the expressions of KLF2 and eNOS mRNAs in HUVECs,
and this effect was blocked with anti–miR-93 or anti–miR-484
(Fig. 4D). Furthermore, NCL S328A overexpression in
HUVECs followed by PS stimulation reduced KLF2 and eNOS
mRNA levels (SI Appendix, Fig. S4D).
The results illustrated in Fig. 4 A–D demonstrate that OS
(mimicked by miR-93, miR-484, or NCL S328A overexpression)
down-regulated KLF2 and eNOS through miR-93 and miR-484
induction. To validate a mechanism involving direct targeting of
miR-93 or miR-484, NCL S328A was overexpressed in HUVECs
followed by AGO2 IP. As illustrated in Fig. 4E, KLF2 and eNOS
mRNA levels were elevated in the AGO2 immunoprecipitates
and were inhibited by the overexpression of anti–miR-93 or anti–
miR-484. Furthermore, KLF2 and eNOS protein expression was
enhanced in cells transfected with wild type and treated with
AICAR. Moreover, NCL S328D and NCL S328A had opposite
effects in regulating the expression of KLF2 and eNOS (Fig. 4F).
To determine if the down-regulation of KLF2 and eNOS by
miR-93 or miR-484 attenuated NO bioavailability, HUVECs
were transfected with NCL S328D or NCL S328A with or without
anti–miR-93 or anti–miR-484 cotransfection. In comparison
with NCL S328D-transfected HUVECs, NO bioavailability
was attenuated in NCL S328A-transfected HUVECs. How-
ever, this attenuation was blocked by cotransfected anti–miR-
93 or anti–miR-484 (Fig. 4G). Consistent with these results,
the mRNA levels of KLF2 and eNOS were both suppressed in
the TA region of EC-AMPKα2−/− mice, compared with that in
the TA of EC-AMPKα2+/+ littermates (Fig. 4H). Taken to-
gether, the results summarized in Fig. 4 demonstrate that OS
down-regulates KLF2 and eNOS, therefore causing EC dys-
function, in part by increasing miR-93 and miR-484 processing
via dephosphorylated NCL.
NCL Regulation of miR-93 and miR-484 Is Involved in Coronary Artery
Disease. Given that miR-93 and miR-484 were both OS-induced
and collectively down-regulated KLF2 and eNOS transcripts that
play key roles in regulating endothelial homeostasis, we com-
pared the serum levels of miR-93 and miR-484 in coronary
artery disease (CAD) (n = 52) patients to healthy controls (HC)
(n = 45) in a discovery cohort (demographics shown in SI
Appendix, Table S3). The levels of miR-93-3p, miR-93-5p, and
miR-484 were significantly higher in CAD patients compared
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Fig. 4. NCL-miR-93 and NCL-miR4-84 down-regulates KLF2 and eNOS. (A and B) RNA-seq datasets from OS/PS experiments (18) cross-referenced to those of
miR-93 or miR-484 overexpression datasets (GSE86497 and GSE66844). Points in dark blue indicate down-regulated genes in both OS/PS and miR-93 or miR-
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Data are mean ± SEM from three independent experiments.
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with HC individuals (Fig. 5 A, C, and E). Similar results were
obtained in the validation cohort containing 32 CAD patients
and 31 HC individuals (Fig. 5 B, D, and F and SI Appendix, Table
S4). Because miR-93 and miR-484 are coregulated by the AMPK–
NCL axis (Fig. 3), we examined whether the levels of miR-93-3p,
miR-93-5p, and miR-484 were mutually correlated in the sera of
CAD patients. As illustrated in Fig. 5G, positive correlation was
found not only between miR-93-3p and miR-93-5p, but also be-
tween miR-93-3p and miR-484 as well as miR-93-5p and miR-484.
Collectively, these results suggest that the athero-prone flow-
induced miR-93 and miR-484 were elevated in the circulation of
most patients diagnosed with CAD in two cohorts.
Discussion
In this investigation, systems studies, including in silico, in vitro,
and in vivo experiments, identified shear stress-regulated RNA
binding proteins that affect EC biology. The results demonstrate
that dephosphorylated NCL under OS facilitates the processing
of miR-93 and miR-484, which target KLF2 and eNOS mRNAs
to decrease their expression. Moreover, we provide evidence that
the PS-activated AMPK regulates miR processing via the phos-
phorylation of NCL (see Fig. 5H for summary). In addition to
KLF2 and eNOS, miR-93 and miR-484 were predicted to target
many other genes (e.g., bone morphogenetic protein receptor
type II) that are also suppressed by OS (Datasets S3 and S4).
Thus, NCL-mediated processing of miR-93 and miR-484 repre-
sents a mechanotransduction mechanism by which the athero-
prone flow down-regulates genes critical for EC homeostasis.
Previous studies on mechano-sensitive miRs focused mainly on
individual miRNAs, and lack a systems view of their effects on EC
function and related diseases (25). Through the identification of a
shear stress-regulated miR-binding protein (i.e., NCL) and its
regulation at the posttranslational level (i.e., AMPK phosphory-
lation), our study provides a more comprehensive understanding
of the miR networks regulated by shear stress. Moreover, the
levels of miR-93 and miR-484 in CAD patient sera, compared
with healthy controls, provide a translational implication. The
possibility that miR-93 and miR-484 inhibitors have therapeutic
benefits deserves further study.
NCL has diverse cellular functions, including transcription,
ribosome biogenesis, and angiogenesis, that depend on its cel-
lular localization in response to various stimuli (26). Here, we
demonstrate that in response to AMPK activation, phosphory-
lated NCL is sequestered in the nucleus (Fig. 2 A) and impedes
premiR-93 and premiR-484 processing by Drosha (Figs. 2 B and
C and 3C). The underlying mechanism involves the translocation
of phosphorylated NCL from cytoplasm into the nucleus, which
inhibits NCL binding Drosha/premiR complexes. In this manner,
dephosphorylated NCL would function as a miR nucleus-to-
cytoplasm shuttle protein to facilitate the miRISC complex as-
sembly, thus demonstrating AMPK regulation of miR process-
ing. This study focused on the processing of miR-93 and miR-484
by NCL, because of the conservation of the NCL-miR binding
sites among mammalian species. Using differentially regulated
OS vs. PS miR transcriptomics (27), our bioinformatics analysis
identified 17 miRs in addition to miR-93 and miR-484 that are
likely to be regulated by AMPK phosphorylation of NCL (SI
Appendix, Table S2). For example, miR-92a is up-regulated by
OS and also predicted to require NCL for processing (SI Ap-
pendix, Table S2) (6). Additionally, among the miRs containing
the NCL binding sequence (Fig. 2E and SI Appendix, Table S1),
miR-219, miR-219-1, and miR-219A-1 are highly homologs to
one another. Thus, it is likely that these miRs are orthologs and
may require NCL for processing. Thus, OS may regulate, via
dephosphorylated NCL, the processing of a network of miRs,
which collectively contribute to a transcriptional profile related
to dysfunctional endothelium.
In silico prediction of miR/mRNA targeting cannot always be
validated experimentally. To enhance the validity of in silico
predictions, miR targeting analyses should be correlated not only
with the expression level of the target mRNAs (28), but also with
changes in cellular functions. In this study, bioinformatics pre-
diction together with biological validation identified that miR-93
and miR-484 target eNOS and KLF2 mRNA. In line with this,
anti–miR-93 and anti–miR-484 can rescue NO bioavailability
(Fig. 4) (6, 24). Although there are a number of mechanisms that
regulate the expression of eNOS, including transcriptional in-
duction by KLF2 (6) and direct phosphorylation (29), miR-93
and miR-484 overexpression was adequate at inhibiting its ex-
pression in PS-stimulated ECs. Although a direct interaction be-
tween miR-93 and miR-484 was not observed, our findings indicate
that they are coregulated by NCL and have similar effects on re-
ducing NO bioavailability. Furthermore, miR-93 and miR-484 are
predicted to coregulate a number of targets (Datasets S3 and S4).
Collectively, both miR-93 and miR-484 are able to affect eNOS
expression directly by targeting eNOS mRNA and indirectly by
inhibiting KLF2 induction. Indeed, anti–miR-93 and anti–miR-484
were able to synergistically restore NO bioavailability (Fig. 4G).
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Fig. 5. Higher miR-93 and miR-484 levels in CAD patients. Sera were isolated from patients with CAD (n = 56) or HCs (n = 10) in the discovery cohort (A, C, and
E) and the validation cohort (n = 32 and 31, respectively in B, D, and F) and the levels of miR-93-3p, miR-93-5p, and miR-484 were measured. Gray boxes
represent the mean and the first and third quantiles; *P < 0.05 (G) Correlation among levels of miR-93-3p, miR-93-5p, and miR-484 were found in combined
CAD and control samples from both cohorts. (H) Graphical abstract of the PS and OS regulation of the NCL-miR93/484 axis via AMPK phosphorylation of NCL,
which results in EC homeostasis versus dysfunction.
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Although AMPK can directly phosphorylate eNOS, this anti–miR-
93/anti–miR-484–mediated restoration is likely due to changes in
eNOS protein abundance because the experiment was conducted in
the absence of AMPK agonists (29). Consistent with these conclu-
sions are the reports of elevated miR-93 levels found in the vascular
wall of subjects with aortic aneurisms (30) and the positive correla-
tion between elevated serum cholesterol and miR-93 levels in human
patients (31). However, a negative correlation has been found be-
tween miR-93 and ABCA1 levels in macrophages, which impair
cholesterol efflux (31). Additionally, elevated miR-484 levels are
positively correlated with carcinoma aggressiveness (32). Taken to-
gether, we find that miR-93 and miR-484 play a role in endothelial
dysfunction and by inference in cardiovascular disease. Indeed, anti–
miR-93 and anti–miR-484 had an additive effect to restore NO
bioavailability, which is a hallmark of EC homeostasis (6, 24).
In summary, this study provides evidence that the AMPK–NCL
axis regulates miR processing. This finding identified a previously
unknown role for NCL in endothelial biology in the context of
cardiovascular health and disease.
Materials and Methods
Experimental methods are described in detail in SI Appendix, SI Materials
and Methods. All cells were housed in an incubator filled with 5% CO2
and cultured according to standard protocols. ChIP assays and immuno-
blotting were conducted according to protocols published by ABcam. A
Bio-Rad CFX96 real-time PCR detection system was used with SYBR green
(Bio-Rad) for all experiments requiring qPCR analysis. All primers used for
ChIP and standard qPCR experiments are displayed in SI Appendix, Tables
S5 and S6. Bioinformatic analyses were conducted in R programming
language with support from Comprehensive R Archive Network (CRAN)
and Bioconductor libraries. The human serum studies were approved by
the institutional ethics committee of Taipei Veterans General Hospital
(discovery cohort) and Xi’an Jiaotong University Medical School (valida-
tion cohort).
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